^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

HuMax-EGFR (zalutumumab)

Associations
Trials
Company:
Genmab
Drug class:
EGFR inhibitor
Related drugs:
Associations
Trials
4ms
Enhancing neutrophil cytotoxicity of a panel of clinical EGFR antibodies by Fc engineering to IgA3.0. (PubMed, Mol Cancer Ther)
Therefore, we reformatted six therapeutic EGFR antibodies (cetuximab, panitumumab, nimotuzumab, necitumumab, zalutumumab, and matuzumab) into the IgA3.0 format, which is an IgA2 isotype that has been adapted for clinical application. IgA3.0 matuzumab exhibited reduced receptor internalization compared to the other antibodies, possibly accounting for its superior in vivo Fc-mediated tumor cell killing efficacy. In conclusion, reformatting EGFR antibodies into an IgA3.0 format increased Fc-mediated killing while retaining Fab-mediated functions and could therefore be a good alternative for the currently available antibody therapies.
Journal
|
EGFR (Epidermal growth factor receptor)
|
Erbitux (cetuximab) • Vectibix (panitumumab) • TheraCIM (nimotuzumab) • Portrazza (necitumumab) • HuMax-EGFR (zalutumumab) • matuzumab (EMD 72000)
5ms
Anti‑epidermal growth factor receptor monoclonal antibody therapy in locally advanced head and neck cancer: A systematic review of phase III clinical trials. (PubMed, Med Int (Lond))
Nimotuzumab (one trial), zalutumumab (one trial) and panitumumab (one trial) were the monoclonal antibodies evaluated in the remaining three trials. Finally, three phase III trials tested the effectiveness of cetuximab plus RT in the treatment of human papillomavirus-positive oropharyngeal carcinoma, and found it to be inferior compared with cisplatin-RT in terms of OS, PFS and failure-free survival. Based on the aforementioned findings, it is difficult to conclude that anti-EGFR therapy in any form has an advantage over conventional chemoradiation in the treatment of LAHNSCC.
P3 data • Review • Journal • Metastases
|
EGFR (Epidermal growth factor receptor)
|
Erbitux (cetuximab) • cisplatin • Vectibix (panitumumab) • TheraCIM (nimotuzumab) • HuMax-EGFR (zalutumumab)
almost3years
Epidermal Growth Factor Receptor as Target for Perioperative Elimination of Circulating Colorectal Cancer Cells. (PubMed, J Oncol)
Three different anti-EGFR mAbs (cetuximab, zalutumumab, and panitumumab) were equally efficient in the opsonization of tumor cell lines. These data support the use of a low dose of anti-EGFR mAbs prior to resection of the tumor to eliminate CTCs without interfering with the healing of the anastomosis. Ultimately, this may reduce the risk of metastasis development, consequently improving long-term patient outcome significantly.
Journal
|
EGFR (Epidermal growth factor receptor)
|
Erbitux (cetuximab) • Vectibix (panitumumab) • HuMax-EGFR (zalutumumab)
over3years
Immune-checkpoint inhibitors versus other systemic therapies in advanced head and neck cancer: a network meta-analysis. (PubMed, Immunotherapy)
Nivolumab was the most favorable treatment. Zalutumumab and buparlisib + paclitaxel had better efficiency, and might be a better selection for patients with programmed death-ligand 1-low/negative tumors than other treatments.
Retrospective data • Journal • Checkpoint inhibition
|
PD-L1 (Programmed death ligand 1)
|
Opdivo (nivolumab) • paclitaxel • buparlisib (AN2025) • HuMax-EGFR (zalutumumab)